Zealand pays Chinese OTR US$30m upfront to expand obesity pipeline
Danish Zealand Pharma A/S partners with Chinese start-up OTR Therapeutics Co. Ltd to expand oral obesity pipeline in US$30m upfront deal.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2201 entries already.
Entries by Thomas Gabrielczyk
Lilly‘s retatrutide delivers record weight loss
Lilly’s triple weight loss combination therapy retatrutide has shown 28.7% weight loss in Phase 3, but higher discontinuations vs. tirzepatide and semaglutide.
Pfizer presents data for Tukysa in HER2-positive breast cancer
Pfizer’s Tukysa improves progression-free survival in first-line HER2-positive breast cancer, especially in HR-negative patients, with manageable safety. Data were shown at the 2025 San Antonio Breast Cancer Symposium.
Roche presents details on breast cancer pill giredestrant
Roche has unveiled detailed data for its oral selective estrogen receptor degrader (SERD), giredestrant, at the 2025 San Antonio Breast Cancer Symposium.
Disco Pharmaceuticals GmbH expands seed financing
Cologne-based Disco Pharmaceuticals GmbH has closed its seed financing at €36m. The company will use the proceeds to advance its surfaceome-mapping platform, developing bispecific ADCs and T-Cell Engagers for hard-to-treat cancers.
Tetraneuron secures funding for Alzheimer’s gene therapy trial
Spanish Tetraneuron secures financing to advance its E2F4DN-based Alzheimer’s gene therapy, restoring neuronal homeostasis and halting disease progression in Europe.
Cellular Origins secures major CGT funding breakthrough
UK-bad Cellular Origins Ltd raised $40m to scale global CGT manufacturing with robotic automation, boosting access to cell therapies and enabling commercial growth.
SLAS announces finalists for the 2026 Ignite Award
The Society for Laboratory Automation and Screening (SLAS) has unveiled the Ignite Award finalists: eight pioneering lab automation and drug discovery start-ups competing for $5,000 at SLAS 2026 in Boston, 7-11 February 2026.
Melt&Marble secures €7.3m Series A to scale designer fats
Swedish Melt&Marble AB has raised €7.3m to scale precision-fermented designer fats for sustainable, high-performance food and personal care ingredients.
Poolbeg takes centre stage in CRS research
Cancer immunotherapies can save lives, yet their side effect — cytokine release syndrome (CRS) — remains a barrier for wider use, even though IL 6 receptor antagonists can treat it. Now the UK company Poolbeg Pharma plc, together with Johnson & Johnson, investigates how CRS might be prevented. The programme is backed by a £3.4m grant from the MRC.